A Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain
艾塞那肽作为尼古丁贴片辅助戒烟和预防戒烟后体重增加的随机对照试验
基本信息
- 批准号:10367010
- 负责人:
- 金额:$ 60.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAddressAftercareAgonistAmericanAmphetaminesAttenuatedBiochemicalBody WeightBrainBupropionCarbon MonoxideCause of DeathCessation of lifeChronic DiseaseCigaretteClinicalCocaineCombined Modality TherapyCounselingCuesDataDiabetes MellitusDiseaseDouble-Blind MethodDouble-blind trialEnergy IntakeEnrollmentEnsureEventEvent-Related PotentialsFoodFrightGLP-I receptorGoalsHealthHyperglycemiaIndividualLightMeasuresMetabolicMetabolic syndromeMorbidity - disease rateNicotineNon-Insulin-Dependent Diabetes MellitusObesityOutcome MeasureOutcome StudyOverweightPatient Self-ReportPersonsPharmaceutical PreparationsPhase III Clinical TrialsPilot ProjectsPlacebosPrediabetes syndromePrevalenceRandomizedRandomized Clinical TrialsRandomized Controlled TrialsRelapseReportingResearchResearch PersonnelResourcesRewardsRisk FactorsSample SizeScientistSiteSmokerSmokingSmoking Cessation InterventionSmoking PreventionStimulusTestingTimeTobacco Use DisorderTobacco useVulnerable PopulationsWeightWeight GainWomanWorkalcohol effectattenuationcigarette smokecigarette smokingdietarydisabilityemotional stimulusexenatideexercise programimprovedinnovationmortalitynicotine patchnicotine replacementnovelnovel strategiesobesity riskplacebo controlled studypre-clinicalpreclinical studyprematureprimary outcomerecruitrelapse riskresponsesmoking abstinencesmoking cessationvarenicline
项目摘要
PROJECT ABSTRACT
Despite reductions in prevalence over the last few decades, over 34 million Americans currently smoke
cigarettes, and tobacco use remains the leading preventable cause of death, disability, and disease. Among
smokers who achieve abstinence, post-cessation weight gain (PCWG) is common and attributed to increased
energy intake in the first weeks and months after quitting. PCWG is problematic for three reasons. First, many
smokers, especially women, report fear of PCWG as a major barrier to quitting. Second, PCWG can precipitate
a relapse. Third PCWG can contribute to the onset of a chronic illness, such as obesity or type 2 diabetes
mellitus. First-line treatments, i.e. nicotine replacement therapies (NRT), varenicline and bupropion help
people quit smoking but do not provide a clinically meaningful impact on PCWG. Our recent pilot work showed
that a 6-week treatment with a glucagon-like peptide-1 receptor (GLP-1R) agonist, extended-release exenatide,
as an adjunct to nicotine patch, improved abstinence and decreased PCWG in prediabetic and/or overweight
treatment-seeking smokers. These findings, which are consistent with preclinical reports that GLP-1R agonists
decrease the rewarding effects of nicotine and food, support GLP-1R as a promising target for facilitating
smoking cessation and decreasing PCWG. The proposed research will assess the efficacy of extended-release
exenatide as an adjunct to nicotine patch on smoking abstinence and PCWG during the first 3 months after
quitting, when most weight gain occurs. A double-blind trial is proposed in which treatment-seeking smokers
will be randomized to receive either 2 mg exenatide (once a week) or placebo as an adjunct to nicotine patch for
14 weeks, starting 2 weeks prior to target quit day. The primary outcome measures will be end-of-treatment
smoking abstinence (4-week continuous) and PCWG. We predict that exenatide will improve abstinence and
mitigate PCWG relative to placebo. Exploratory aims will examine the long-term (6 months) impact of
exenatide on the primary study outcomes and the effect of exenatide on neuroaffective responses to food- and
nicotine-related stimuli. Innovative aspects of this research include: 1) targeting GLP-1R to facilitate smoking
cessation and decrease PCWG; 2) testing an approved medication that could be deployed quickly as an
adjunctive treatment for use in combination with NRT; 3) providing the impetus for conducting pivotal Phase 3
clinical trials to establish the efficacy of exenatide-NRT combinations and 4) exploring a putative mechanism
implicated in exenatide's effects on smoking and PCWG. This project stands to contribute significantly to
current treatments for smoking cessation by identifying a first-in-class adjunct pharmacotherapeutic that
uniquely targets both cessation and weight gain. This R01 resubmission application is proposed by an early-
stage investigator who has assembled a team of scientists with relevant expertise and access to resources,
including two-site recruitment capabilities, to ensure timely enrollment and successful completion of a large
sample size (N=216).
项目摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER D VERRICO其他文献
CHRISTOPHER D VERRICO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER D VERRICO', 18)}}的其他基金
A Human Laboratory Study of Exenatide for Reducing the Reinforcing Effects of Cocaine
艾塞那肽减少可卡因增强作用的人体实验室研究
- 批准号:
10573011 - 财政年份:2023
- 资助金额:
$ 60.24万 - 项目类别:
A Randomized Controlled Trial of Exenatide as an Adjunct to Nicotine Patch for Smoking Cessation and Prevention of Post-Cessation Weight Gain
艾塞那肽作为尼古丁贴片辅助戒烟和预防戒烟后体重增加的随机对照试验
- 批准号:
10649417 - 财政年份:2022
- 资助金额:
$ 60.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 60.24万 - 项目类别:
Research Grant